IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Efficacy and Safety,Long-term Study of Low-dose Oral Contraceptive Pill to Treat Dysmenorrhea.
This study has been completed.
Sponsor:
Nobelpharma
Information provided by:
Nobelpharma
ClinicalTrials.gov Identifier:
NCT00212277
First received: September 13, 2005
Last updated: September 9, 2010
Last verified: September 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this long-term study is to determine whether combination oral contraceptive pill of Norethindrone & Ethinyl estradiol is effective in the treatmentof dysmenorrhea associated with endometriosis.
| Condition | Intervention | Phase |
|---|---|---|
| Dysmenorrhea | Drug: Norethindrone,Ethinyl Estradiol | Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment |
| Official Title: | Phase3,Open-label,Long-term,NSAID-Add-on,Clinical Trial of Mono-phase Low-dose Oral Contraceptive Pill for Treatment of Dysmenorrhea Associated With Endometriosis. |
Resource links provided by NLM:
Further study details as provided by Nobelpharma:
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- dysmenorrhea associated with endometriosis
Exclusion Criteria:
- severe hepatopathy
- pregnant woman
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00212277
Please refer to this study by its ClinicalTrials.gov identifier: NCT00212277
Sponsors and Collaborators
Nobelpharma
Investigators
| Study Director: | Naoki Terakawa, M.D.,Ph.D. | Tottori University,Tottori,Japan |
More Information
| ClinicalTrials.gov Identifier: | NCT00212277 History of Changes |
| Other Study ID Numbers: |
IKH-01-5 |
| Study First Received: | September 13, 2005 |
| Last Updated: | September 9, 2010 |
Additional relevant MeSH terms:
|
Dysmenorrhea Menstruation Disturbances Pathologic Processes Pelvic Pain Pain Neurologic Manifestations Signs and Symptoms Estradiol Ethinyl Estradiol Contraceptive Agents Norethindrone |
Norethindrone acetate Contraceptives, Oral Contraceptives, Oral, Combined Estrogens Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Reproductive Control Agents Contraceptive Agents, Female Contraceptives, Oral, Synthetic |
ClinicalTrials.gov processed this record on August 18, 2017